Stroke treatment showdown: is removing the clot alone enough?

NCT ID NCT05827042

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two treatments for a severe type of stroke caused by a blockage in a major artery at the base of the brain. Some patients will get a clot-busting drug through a vein followed by a procedure to remove the clot, while others will have the clot removal procedure alone. The goal is to see if skipping the drug leads to similar or better recovery and safety. About 338 adults who can be treated within 4.5 hours of stroke onset will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Alteplase or Tenecteplase (clot-busting drugs given through a vein)

What this could lead to

If successful, this could show that removing the clot directly is just as good or better than giving a clot-busting drug first, potentially simplifying treatment for this severe stroke type.

What could go wrong

This is a Phase 3 trial but still relatively small (338 people). The results may not apply to all stroke patients, and there is a risk that skipping the clot-busting drug could lead to worse outcomes or more disability.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BASILAR ARTERY OCCLUSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

basilar artery occlusion stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of University of Science and Technology of China

    RECRUITING

    Hefei, Anhui, 230001, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••